At a time when the left-liberal intelligentsia is leaving no stone unturned to discredit Made in India vaccines, especially the indigenously developed Covaxin, Bharat Biotech has decided to pay compensation to the recipients of the vaccines in the case of severe side effects.
In a welcome move, which will go a long way in tackling the fear psychosis created by the left-liberal media over Covaxin, Bharat Biotech has stated that the company will pay compensation to the recipients of the antidote in the case of severe side effects.
“In case of any adverse events or serious adverse events, you will be provided a medically recognised standard of care in the government designated and authorised centres/hospitals,” states the consent form to be signed by the vaccine recipients. Bharat Biotech has received a government purchase order for the supply of 55 lakh doses of Covaxin.
The consent form also says, “The compensation for serious adverse event will be paid by the sponsor (BBIL) in case if the SAE is proven to be causally related to the vaccine.”
The prime target of newly turned anti-vaccine activists in India is Covaxin – developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR). The reasons behind the apprehensions of many are simple – how can Covaxin be cleared for emergency use in the country without it completing Phase III trials? Further, without Phase III data, such clowns believe that inoculating Indians with Bharat Biotech’s vaccine would amount to the Indian state playing with their lives. Well, here’s a fact for such unadulterated fools who think Covaxin is ‘unsafe’. That fact is that Covaxin is totally safe.
The jab has cleared Phase I and II trials with flying colours, and it is in these two trials that the ‘safety’ of a vaccine is ascertained. In Phase III trials, researchers get a clearer picture of how ‘efficacious’ a vaccine is among a considerable section of the volunteers, half of whom are given a dud placebo. The phase III trials of Covaxinare in the final stages and results will be out by late January or early February. Subsequently, we will get to know the actual effectiveness of the jab. Mind you, the researchers and regulators, in the know of classified data, have a fairly good idea about the vaccine’s effectiveness already but are not citing the same due to the clinical trials still going on.
“Don’t accuse us of inexperience. We are a global company… have manufactured 16 vaccines. It is not correct to say we are not transparent with data. We conduct clinical trials in many countries, including the UK. The point is we are not an Indian company… but a global one,” said Bharat Biotech’s Chairman, Dr Krishna Ella after a section of Congress leaders like Jairam Ramesh and Shashi Tharoor attacked Covaxin.
Bharat Biotech has set an example and its decision to pay compensation in case of any side effects in a country of over a billion people highlights how the company is supremely confident about the quality and efficacy of Covaxin.